Drug Trial Radar · NCT00035555
Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
Last checked: Nov 20, 2026Latest source record: Jan 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
230
Actual
Start
Mar 2001
Primary completion
Jan 2004
Study completion Jul 2012
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- May 6, 2002
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether treatment with Belatacept (BMS-224818) is as efficacious as treatment with cyclosporine at preventing acute rejection and with a superior safety/tolerability profile (better kidney function and blood pressure, fewer lipid problems, less diabetes mellitus).
Conditions
- Graft Rejection
- Kidney Transplantation
- Renal Transplantation
Interventions
BelataceptDrug
Solution, intravenous
CyclosporineDrug
Oral, capsule
Mycophenolate mofetil (MMF)Drug
Oral, capsule
CorticosteroidsDrug
Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With an Episode of Clinically-suspected and Biopsy-proven Acute Rejection (CSPAR)Time frame: By Month 6 posttransplant (From Day 1 to Month 6)
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Univ. of Calif. - San Francisco
San Francisco, California
Emory Univ. School of Medicine
Atlanta, Georgia
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Univ. of Nebraska Medical Center
Omaha, Nebraska
Saint Barnabas Medical Center
Livingston, New Jersey
Mount Sinai Medical Center
New York, New York
Univ. of Pennsylvania
Philadelphia, Pennsylvania
Medical Univ. of South Carolina
Charleston, South Carolina
Baylor Univ. Medical Center
Dallas, Texas
Univ. of Wisconsin
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.